text_1: Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.
text_2: Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context.